These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 9890717)

  • 21. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers.
    Bijsterveld NR; Moons AH; Boekholdt SM; van Aken BE; Fennema H; Peters RJ; Meijers JC; Büller HR; Levi M
    Circulation; 2002 Nov; 106(20):2550-4. PubMed ID: 12427650
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Major bleeding with old and novel oral anticoagulants: How to manage it. Focus on reversal agents.
    Di Fusco SA; Lucà F; Benvenuto M; Iorio A; Fiscella D; D'Ascenzo F; Madeo A; Colivicchi F; Di Lenarda A; Gulizia MM
    Int J Cardiol; 2018 Oct; 268():75-79. PubMed ID: 29843897
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discussion of "Protocolized warfarin reversal with 4-factor prothrombin complex concentrate versus 3-factor prothrombin complex concentrate with recombinant factor VIIa".
    Van Dusen R
    Am J Surg; 2018 May; 215(5):780-781. PubMed ID: 29366484
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacologic interventions for reversing the effects of oral anticoagulants.
    Kalus JS
    Am J Health Syst Pharm; 2013 May; 70(10 Suppl 1):S12-21. PubMed ID: 23640528
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Race against the clock: overcoming challenges in the management of anticoagulant-associated intracerebral hemorrhage.
    Le Roux P; Pollack CV; Milan M; Schaefer A
    J Neurosurg; 2014 Aug; 121 Suppl():1-20. PubMed ID: 25081496
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recombinant factor VIIa in preterm neonates with prolonged prothrombin time.
    Greisen G; Andreasen RB
    Blood Coagul Fibrinolysis; 2003 Jan; 14(1):117-20. PubMed ID: 12544740
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of fixed low-dose warfarin on hemostatic factors in continuous ambulatory peritoneal dialysis patients.
    Kim SB; Lee SK; Park JS; Chi HS; Hong CD; Yang WS
    Am J Kidney Dis; 2001 Feb; 37(2):343-7. PubMed ID: 11157376
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro.
    Perzborn E; Heitmeier S; Laux V; Buchmüller A
    Thromb Res; 2014 Apr; 133(4):671-81. PubMed ID: 24529498
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of excessive anticoagulant effect due to vitamin K antagonists.
    Dentali F; Crowther MA
    Hematology Am Soc Hematol Educ Program; 2008; ():266-70. PubMed ID: 19074094
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potentiation of vitamin K antagonists by high-dose intravenous methylprednisolone.
    Costedoat-Chalumeau N; Amoura Z; Aymard G; Sevin O; Wechsler B; Cacoub P; Du LT; Diquet B; Ankri A; Piette JC
    Ann Intern Med; 2000 Apr; 132(8):631-5. PubMed ID: 10766681
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recombinant nematode anticoagulant protein c2, a novel inhibitor of tissue factor-factor VIIa activity, abrogates endotoxin-induced coagulation in chimpanzees.
    Moons AH; Peters RJ; Cate Ht; Bauer KA; Vlasuk GP; Büller HR; Levi M
    Thromb Haemost; 2002 Oct; 88(4):627-31. PubMed ID: 12362234
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reversal of new, factor-specific oral anticoagulants by rFVIIa, prothrombin complex concentrate and activated prothrombin complex concentrate: a review of animal and human studies.
    Lee FM; Chan AK; Lau KK; Chan HH
    Thromb Res; 2014 May; 133(5):705-13. PubMed ID: 24666649
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hemostatic agents for bleeding: recombinant-activated factor VII and beyond.
    Franchini M; Crestani S; Frattini F; Sissa C; Bonfanti C
    Semin Thromb Hemost; 2015 Apr; 41(3):342-7. PubMed ID: 24937097
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on prothrombin time, activated partial thromboplastin time, and Ecarin Clotting Time.
    Harder S; Graff J; Klinkhardt U; von Hentig N; Walenga JM; Watanabe H; Osakabe M; Breddin HK
    Thromb Haemost; 2004 Jun; 91(6):1137-45. PubMed ID: 15175800
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Effect of VKORC1 and CYP2C9 variants on dosage of oral anticoagulants in Chilean individuals].
    Benavides F; Grossman N; Poggi H; Nieto E; Bertrán A; Araos D; Vásquez M; Ibarra I; Cáceres F; Espinoza K; Lagos M; Repetto M G
    Rev Med Chil; 2015 Nov; 143(11):1369-76. PubMed ID: 26757860
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Successful control of massive coumarol-induced acute upper gastrointestinal bleeding and correction of prothrombin time by recombinant active factor VII (Eptacog-alpha, NovoSeven) in a patient with a prosthetic aortic valve and two malignancies (chronic lymphoid leukaemia and lung cancer).
    Udvardy M; Telek B; Mezey G; Batar P; Altorjay I
    Blood Coagul Fibrinolysis; 2004 Apr; 15(3):265-7. PubMed ID: 15060425
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Correlation between different intensities of anti-vitamin K treatment and coagulation parameters.
    Jerkeman A; Astermark J; Hedner U; Lethagen S; Olsson CG; Berntorp E
    Thromb Res; 2000 Jun; 98(6):467-71. PubMed ID: 10899345
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An update of consensus guidelines for warfarin reversal.
    Tran HA; Chunilal SD; Harper PL; Tran H; Wood EM; Gallus AS;
    Med J Aust; 2013 Mar; 198(4):198-9. PubMed ID: 23451962
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hematologic effects of recombinant factor VIIa combined with hemoglobin-based oxygen carrier-201 for prehospital resuscitation of swine with severe uncontrolled hemorrhage due to liver injury.
    Arnaud F; Hammett M; Philbin N; Scultetus A; McCarron R; Freilich D
    Blood Coagul Fibrinolysis; 2008 Oct; 19(7):669-77. PubMed ID: 18832908
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of refractory bleeding after cardiac operations with low-dose recombinant activated factor VII (NovoSeven): a propensity score analysis.
    Gelsomino S; Lorusso R; Romagnoli S; Bevilacqua S; De Cicco G; Billè G; Stefàno P; Gensini GF
    Eur J Cardiothorac Surg; 2008 Jan; 33(1):64-71. PubMed ID: 17996457
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.